Education
About Us
Working with TipRanks
Follow Us
Tandem Diabetes Care (DE:TD5A)
:TD5A
TD5A Analyst Ratings
Moderate Buy
8 Buy
6 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TD5A Stock 12 Month Forecast
Average Price Target
€36.78
▲(98.60% Upside)
| Highest Price Target€69.31 | Average Price Target€36.78 | Lowest Price Target€16.63 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Stifel Nicolaus
Reiterated
03/24/25
Lake Street
Reiterated
03/19/25
TD Cowen
Reiterated
03/18/25
Barclays
Reiterated
03/17/25
Leerink Partners
Reiterated
03/10/25
Citi
Downgraded
03/06/25
Morgan Stanley
Downgraded
03/05/25
Wells Fargo
Downgraded
03/03/25
Bernstein
Downgraded
03/03/25
Robert W. Baird
Reiterated
02/27/25
UBS
€36.92→€32.31
Hold
74.45%
Upside
Reiterated
02/27/25
Tandem Diabetes Care (TNDM) PT Lowered to $35 at UBSUBS analyst Danielle Antalffy lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $35.00 (from $40.00) while maintaining a Neutral rating.
Piper Sandler
€50.77→€33.23
Buy
79.44%
Upside
Reiterated
02/27/25
Piper Sandler Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Bank of America Securities
€16.62
Sell
-10.28%
Downside
Reiterated
02/26/25
Sell Rating for Tandem Diabetes Care Due to Revenue Shortfalls and High Valuation
RBC Capital
€60→€50.77
Buy
174.14%
Upside
Reiterated
02/26/25
Tandem Diabetes Care (TNDM) Receives a Buy from RBC Capital
Canaccord Genuity
€58.16
Buy
214.02%
Upside
Reiterated
02/25/25
Tandem Diabetes price target lowered to $58 from $63 at CanaccordTandem Diabetes price target lowered to $58 from $63 at Canaccord
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
Reiterated
03/24/25
Lake Street
Reiterated
03/19/25
TD Cowen
Reiterated
03/18/25
Barclays
Reiterated
03/17/25
Leerink Partners
Reiterated
03/10/25
Citi
Downgraded
03/06/25
Morgan Stanley
Downgraded
03/05/25
Wells Fargo
Downgraded
03/03/25
Bernstein
Downgraded
03/03/25
Robert W. Baird
Reiterated
02/27/25
UBS
€36.92→€32.31
Hold
74.45%
Upside
Reiterated
02/27/25
Tandem Diabetes Care (TNDM) PT Lowered to $35 at UBSUBS analyst Danielle Antalffy lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $35.00 (from $40.00) while maintaining a Neutral rating.
Piper Sandler
€50.77→€33.23
Buy
79.44%
Upside
Reiterated
02/27/25
Piper Sandler Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Bank of America Securities
€16.62
Sell
-10.28%
Downside
Reiterated
02/26/25
Sell Rating for Tandem Diabetes Care Due to Revenue Shortfalls and High Valuation
RBC Capital
€60→€50.77
Buy
174.14%
Upside
Reiterated
02/26/25
Tandem Diabetes Care (TNDM) Receives a Buy from RBC Capital
Canaccord Genuity
€58.16
Buy
214.02%
Upside
Reiterated
02/25/25
Tandem Diabetes price target lowered to $58 from $63 at CanaccordTandem Diabetes price target lowered to $58 from $63 at Canaccord
TD5A Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
11
12
10
11
16
Buy
5
6
5
4
2
Hold
8
6
4
2
6
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
24
24
19
18
25
Each month's total comprises the sum of three months' worth of ratings.
TD5A Financial Forecast
TD5A Stock Forecast FAQ
What is DE:TD5A’s average 12-month price target, according to analysts?
Based on analyst ratings, Tandem Diabetes Care’s 12-month average price target is €36.78.
What is DE:TD5A’s upside potential, based on the analysts’ average price target?
Tandem Diabetes Care has 98.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Tandem Diabetes Care a Buy, Sell or Hold?
Tandem Diabetes Care has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 6 hold ratings and 1 sell ratings.
What is Tandem Diabetes Care’s share price target?
The average share price target for Tandem Diabetes Care is €36.78. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €69.31 ,and the lowest forecast is €16.63. The average share price target represents 98.60% Increase from the current price of €18.52.
The highest analyst share price target is €69.31 ,and the lowest forecast is €16.63. The average share price target represents 98.60% Increase from the current price of €18.52.
What do analysts say about Tandem Diabetes Care?
Tandem Diabetes Care’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of Tandem Diabetes Care?
To buy shares of DE:TD5A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.